MFN2 and polycystic ovary syndrome: Decreased inflammation in the ovary (tumor growth factor and nuclear factor-kB), caspase-6, elevated hypoxia-inducible factor-1α, and decreased histone deacetylase-2 (HDAC2). Ameliorates mitochondrial abnormalities observed in rats with polycystic ovary syndrome, elevates adenosine triphosphate synthase and MFn2. Ameliorates ovarian mitochondrial abnormalities.